Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy

Journal of Infectious Diseases

Volumn 204, Issue 4, 2011, Pages 515-520

  Taiwo, Babafemi ^a   Gallien, Sebastien ^b   Aga, Evgenia ^c   Ribaudo, Heather ^c   Haubrich, Richard ^d   Kuritzkes, Daniel R ^b   Eron Jr , Joseph J ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; EFAVIRENZ; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; RISK FACTOR; VIREMIA;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; RETROSPECTIVE STUDIES; VIREMIA;

EID: 79960877415     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir353     Document Type: Article

References (14)

1. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18:981-9. (Pubitemid 38591188)
2. Pilcher CD, Miller WC, Beatty ZA, Eron JJ. Detectable HIV-1 RNA at levels below quantifiable limits by amplicor HIV-1 monitor is associated with virological relapse in antiretroviral therapy. AIDS 1999; 13:1337-42. (Pubitemid 29408448)
3. Hull M, Loutfy M, Zhang W, et al. Persistent low-level viremia is associated with increased risk of virologic failure and mortality [Abstract 504]. In programs and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, 2010.
4. Parkin NT, Deeks SG, Wrin MT, et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment- experienced patients. AIDS 2000; 14:2877-7.
5. Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39:1030-7. (Pubitemid 39313462)
6. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 2002; 16:1039-44. (Pubitemid 34499427)
7. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72:2422-8. (Pubitemid 28100803)
8. Mackie NE, Phillips AN, Kaye S, et al. Antiretroviral resistance in HIV-1 infected patients with low-level viremia. J Infect Dis 2010; 201:1303-7.
9. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106. (Pubitemid 351679596)
10. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769-81. (Pubitemid 44223101)
11. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-45.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, Department of Health and Human Services. 2009; 1-161. http://www.aidsinfo.nih. gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 10 July 2010.
13. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 2007; 46:547-54. (Pubitemid 350191047)
14. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400. (Pubitemid 40065906)